Goodwin Procter advised Global Blood Therapeutics on the deal.Global Blood Therapeutics, Inc. (Nasdaq: GBT) announced its offering of 1.875% Convertible Senior Notes due 2028. The deal…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
